Import Your Data

FAQ

More QuickView FAQs

QuickView

0
Meta-
Analysis

Bookmark Forward

QuickView for Secretin (compound)

Summary
General Info

DrugBank

Identification

Name:	Secretin
Name (isomeric):	DB00021
Drug Type:	biotech
Description:	A peptide hormone of about 27 amino acids from the duodenal mucosa that activates pancreatic secretion and lowers the blood sugar level. (USAN and the USP Dictionary of Drug Names, 1994, p597)
Synonyms:	Secremax, SecreFlo
Brand:	SecreFlo, Secremax, SecreFlo (Repligen Corp)
Category:	Diagnostic Agents

Pharmacology

Indication:	For diagnosis of pancreatic exocrine dysfunction and gastrinoma
Pharmacology:	Used in the diagnosis of pancreatic dysfunction or gastrinoma (stomach cancer), secretin is a hormone produced in the S cells of the duodenum in response to low local pH. It stimulates the secretion of bicarbonate from bicarbonate producing organs(liver, pancreas, Brunner's glands) when the pH drops below a set value. This helps neutralize the gast... show more » Used in the diagnosis of pancreatic dysfunction or gastrinoma (stomach cancer), secretin is a hormone produced in the S cells of the duodenum in response to low local pH. It stimulates the secretion of bicarbonate from bicarbonate producing organs(liver, pancreas, Brunner's glands) when the pH drops below a set value. This helps neutralize the gastric acid entering the duodenum from the stomach. It also inhibits acid secretion from the stomach by reducing gastrin release from the G cells of the stomach. show less «
Mechanism of Action:	Secretin binds to the secretin receptor found on the lining of S cells in the duodenum and G cells in the stomach. Binding leads to the secrection of bicarbonate or the reduction of the secretion of gastrin. Properly functioning organs (duodenum, pancreas and stomach) should be responsive to this hormone
Affected organisms:	Humans and other mammals

Interactions

Drug interaction:

Trimethobenzamide	The stimulatory effect of Secretin may be reduced by anticholinergics such as Trimethobenzamide. Concomitant use of Secretin and drugs with substantial anticholinergic effects should be avoided. If combination therapy must be used, Secretin efficacy should be closely monitored.
Tiotropium	The stimulatory effect of Secretin may be reduced by anticholinergics such as Tiotropium. Concomitant use of Secretin and drugs with substantial anticholinergic effects should be avoided. If combination therapy must be used, Secretin efficacy should be closely monitored.
Trospium	The stimulatory effect of Secretin may be reduced by anticholinergics such as Trospium. Concomitant use of Secretin and drugs with substantial anticholinergic effects should be avoided. If combination therapy must be used, Secretin efficacy should be closely monitored.
Tolterodine	The stimulatory effect of Secretin may be reduced by anticholinergics such as Tolterodine. Concomitant use of Secretin and drugs with substantial anticholinergic effects should be avoided. If combination therapy must be used, Secretin efficacy should be closely monitored.
Clidinium	Anticholinergic agents such as secretin may diminish the stimulatory effect of secretin. Avoid using drugs with substantial anticholinergic effects in patients receiving secretin whenever possible. If such agents must be used in combination, monitor response to secretin closely.

Targets

Secretin receptor